In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while ...

BOSTON, MA--(Marketwired - May 17, 2016) - Amazing Charts, LLC, a leading developer of Electronic Health Record (EHR) and Practice Management (PM) systems for independent physician practices, today ...

At 6-month follow-up, a single 240 mg dose of WVE-007 (INHBE GalNAc-siRNA) continued to drive significant placebo-adjusted reductions in visceral fat (-14%; p WVE-007 led to greater improvement in ...

Dose-dependent mean reductions of Activin E of up to 85% one month post single dose of WVE-007 in INLIGHT clinical trial, exceeding levels that led to weight loss in preclinical models; WVE-007 is ...

LONDON--(BUSINESS WIRE)--Intertek, a Total Quality Assurance provider to industries worldwide, announces the launch of Inlight™ Advantage, a new service-offering designed to accelerate a customer’s ...

The University of Toronto has launched Inlight, an Institutional Strategic Initiative that aims to improve post-secondary student mental health and wellness by investing in impactful research and ...

Digital product agency Inlight has launched a new service offering, the Digital Experience Benchmark, to help businesses evaluate the user experience (UX) of a digital product or service against a ...

LONDON--(BUSINESS WIRE)--Intertek, a leading Total Quality Assurance provider to industries worldwide, is pleased to unveil its recently rebranded, end-to-end Supply Chain Risk Management solution, ...

In Phase 1 portion of trial, WVE-007 improved body composition by inducing fat loss, including harmful visceral fat, while maintaining muscle; data continue to support once or twice-yearly dosing Phas ...

CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE)-- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform ...